Twenty point six percent of patients followed a switcher trajectory within 12 months, with higher persistence seen for switchers.

November 7, 2008 — Extended therapy with buprenorphine-naloxone (Suboxone, Reckitt Benckiser Pharmaceuticals) substantially improves outcomes in opioid-addicted youth and might offer clinicians a new, ...

Dual therapy with a GLP-1 receptor agonist plus ixekizumab demonstrates long-term benefits in psoriatic disease activity, ...

Please provide your email address to receive an email when new articles are posted on . Of 145,410 adults who began a GLP-1 drug, 76 developed thyroid cancer over a mean 3.9 years of follow-up. Risk ...

New research to be presented at the European Congress on Obesity (ECO 2025, Malaga, Spain, 11–14 May) shows that patients using GLP-1 or combined GLP-1 / GIP receptor agonist therapy for weight loss ...

Following ablation for AF, GLP-1 agonist therapy is associated with decreased risk for AF recurrence in patients with type 2 diabetes. Glucagon-like peptide-1 receptor (GLP-1) agonist use is ...

Retrospective cohorts show GLP-1 RA exposure yields ~5% relative weight reduction and an apparent OS advantage, while ...

New platform connects patients with licensed providers offering sermorelin under medical supervision, supported by a growing body of peer-reviewed research and an emerging community of clinicians and ...

Patients with diabetes being managed with GLP-1R agonists can expect a slight decrease in intraocular pressure. Glucagon-like peptide-1 receptor (GLP-1R) agonist therapy used for the treatment of ...

GLP-1 receptor agonists are linked to a 55% reduction in mortality risk in women with ovarian cancer, based on a retrospective cohort study. The study utilized data from the TriNetX Research Network, ...